Laura Sinatra

Laura Sinatra

Auto-generated profile, based on publicly available information

Laura Sinatra

Institute for Drug Discovery Medical Faculty Leipzig University Brüderstr. 34 04103 Leipzig Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2018 in Chemical Science
Verified
Journal Article
Open access
PDF file
BSBenjamin J. Stenton
Benjamin J. Stenton
BOBruno Oliveira
Bruno Oliveira
MMMaria Matos
Maria Matos
LSLaura Sinatra
Laura Sinatra
GBGonçalo J. L. Bernardes
Gonçalo J. L. Bernardes
We describe the development of a bifunctional linker that simultaneously allows site-specific protein modification and palladium-mediated bioorthogonal decaging.

11 August 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
LSLaura Sinatra
Laura Sinatra
Jan BandolikJan Bandolik
Jan Bandolik
MRMartin Roatsch
Martin Roatsch
MSMelf Sönnichsen
Melf Sönnichsen
CSClara T. Schoeder
Clara T. Schoeder
FHFinn K. Hansen
Finn K. Hansen
Inhibition of more than one cancer‐related pathway by multi‐target agents is an emerging approach in modern anticancer drug discovery. Here, based on the well‐established synergy between histone deacetylase inhibitors (HDACi) and alkylating agents, we present the discovery of a series of alkylating HDACi using a pharmacophore‐linking strategy. For the parallel synthesis of the target compounds, we developed an efficient solid‐phase‐supported protocol using hydroxamic acids immobilized on resins (HAIRs) as stable and versatile building blocks for the preparation of functionalized HDACi. The most promising compound, 3 n, was significantly more active in apoptosis induction, activation of caspase 3/7, and formation of DNA damage (γ‐H2AX) than the sum of the activities of either active principle alone. Furthermore, to demonstrate the utility of our preloaded resins, the HAIR approach was successfully extended to the synthesis of a proof‐of‐concept proteolysis‐targeting chimera (PROTAC), which efficiently degrades histone deacetylases.

19 February 2021 in Chempluschem
Verified
Journal Article
Open access
PDF file
LSLaura Sinatra
Laura Sinatra
LKLisa Kolano
Lisa Kolano
MIMaik Icker
Maik Icker
SFStefan R. Fritzsche
Stefan R. Fritzsche
DVDaniela Volke
Daniela Volke
FHFinn K. Hansen
Finn K. Hansen
α‐Aminoxy peptides represent an interesting group of peptidomimetics with high proteolytic stability and the ability to fold into specific, predictable secondary structures. Here, we present a series of hybrid peptides consisting of α‐aminoxy acids and α‐amino acids with cationic and aromatic, hydrophobic side chains in an alternating manner synthesized using an efficient protocol that combines solution‐ and solid‐phase synthesis. 2D ROESY experiments with a representative hexamer suggested the presence of a 7/8 helical conformation in solution. Biological evaluation revealed a significant impact of the peptide chain length and the N‐terminal cap on the antimicrobial and anticancer properties of this series of hybrid peptides. The Fmoc‐capped peptide 6e displayed the most potent antimicrobial activity against a panel of Gram‐negative and Gram‐positive bacterial strains (e. g. against E. Coli: MIC=8 mg/L; S. aureus: MIC=4 mg/L).

11 August 2020 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
LSLaura Sinatra
Laura Sinatra
Jan BandolikJan Bandolik
Jan Bandolik
MRMartin Roatsch
Martin Roatsch
MSMelf Sönnichsen
Melf Sönnichsen
CSClara T. Schoeder
Clara T. Schoeder
FHFinn K. Hansen
Finn K. Hansen
Multi‐Target‐Wirkstoffe stellen in der modernen Tumortherapie einen vielversprechenden Ansatz dar. Basierend auf dem bekannten Synergismus zwischen Histon‐Deacetylase‐Inhibitoren (HDACi) und alkylierenden Zytostatika präsentieren wir in dieser Arbeit die Entwicklung von alkylierenden HDACi, welche aus einer Pharmakophor‐Verknüpfungsstrategie hervorgegangen sind. Für die Synthese haben wir ein Protokoll entwickelt, bei dem Hydroxamsäuren an Festphasenharze immobilisiert und als vielseitig anwendbare Bausteine für die Synthese von funktionalisierten HDACi verwendet wurden. Verbindung 3 n zeigt eine signifikant bessere Induktion der Apoptose, Caspase‐3/7‐Aktivierung und Erzeugung von DNA‐Schäden als die Summe der biologischen Aktivitäten der einzelnen Pharmakophore. Um die Vielseitigkeit unserer beladenen Harze zu demonstrieren, wurde dieses Konzept auf die Synthese eines HDAC‐PROTAC 4 übertragen. Western‐Blot‐Experimente bestätigten, dass PROTAC 4 den Abbau von HDACs effizient induziert.